Press Release: CILcare, CBSET, and Draper partner to accelerate hearing loss treatment and care

CAMBRIDGE, Mass., Nov. 6, 2017 – CILcare Inc., the world’s leading clinical research organization specializing in ear disorders, and CBSET Inc., a non-profit translational research institute specializing in the advancement of novel therapies, announced today the initiation of a collaboration with Draper, a not-for-profit technology development company focused on the design, development and deployment of […]

Press Release: CBSET Chairman Elazer Edelman, MD, PhD, has received the “TCT 2017 Career Achievement Award”

LEXINGTON, Mass., November 1, 2017  — CBSET Inc., a non-profit translational research institute that specializes in the advancement of novel therapies, announced today that Internationally renowned cardiologist, Elazer Edelman, MD, PhD, has received the “TCT Career Achievement Award” at TCT 2017 in Denver, Colorado. TCT Directors, Martin B. Leon, MD, and Gregg W. Stone, MD, […]

Press Release: Lesion Preparation Using Diamondback 360® Orbital Atherectomy System Enhances Paclitaxel Distribution in Calcified Peripheral Arteries: CBSET Data Published in Journal of Controlled Release

“This preclinical demonstration of the hindrance of drug distribution by calcified tissue and improved drug delivery after modification of calcified atherosclerotic plaque could have significant clinical implications.” – Michael R. Jaff*, D.O. President, Newton-Wellesley Hospital; Professor of Medicine, Harvard Medical School LEXINGTON, Mass., September 11, 2017  — CBSET Inc., a not-for-profit preclinical research institute dedicated to […]

Press Release: CBSET and CILcare partner to offer cutting-edge preclinical research services for the evaluation of hearing disorders and regenerative therapies

– “This partnership brings together CBSETs preclinical surgery, drug delivery, and histopathology expertise with CILcare’s proprietary functional tests for assessing alterations to the auditory system in GLP-compliant state-of-the-art facilities. Our new services will enable companies to accelerate their development of novel therapies for hearing loss and be instrumental in supporting their regulatory submissions.” – Peter […]

Press Release: CBSET expands its preclinical research services by adding GLP-compliant cell-based-therapies support capability

Company to launch new service at next week’s “ISSCR 2017 Annual Meeting” “CBSET is the ideal partner in preparing, presenting, and defending GLP studies for regulatory review.”—Michael Naimark, CBSET LEXINGTON, Mass., June 8, 2017  — CBSET Inc., a non-profit GLP translational research institute that specializes in the advancement of novel therapies, announced today that it has […]

Press Release: Safety and Efficacy of New Class of Orthopedic Implant for Intramedullary Biologic Stabilization of Fractured Long Bones Studied Out to 1 Year

CBSET, IlluminOss Medical Data Published in Journal of Orthopaedic Research IlluminOss* System provides minimally invasive approach designed to replace splints, casts, metal fixator plates and rods to stabilize broken bones LEXINGTON, Mass., March 23, 2017 — CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, announced today it […]

Press Release: CBSET appoints Rami Tzafriri PhD as Director of Research and Innovation

LEXINGTON, Mass., Oct 28, 2016 — CBSET Inc. announced today that it has appointed Dr. Rami Tzafriri as Director of Research and Innovation. Since 2009, Dr. Tzafriri has held the position of Principal Scientist at CBSET, where he developed quantitative computational and experimental methods for evaluating combination drug and energy delivery devices. He is best known […]

Press Release: CBSET appoints Michael Naimark as Director of Business Development

LEXINGTON, Mass., Oct 27, 2016 — CBSET, Inc. announced today that it has appointed Michael Naimark as Director of Business Development, effective immediately. Most recently, he was employed by the Neural Stem Cell Institute (NSCI) as project manager overseeing the development of a cell-based therapy for macular degeneration under a 4-year award from the New York Stem […]

News Advisory: You Need To Know: Endovascular Drug Delivery Is Experiencing a Resurgence in Innovation

“Understanding and computationally modeling the determinants of drug release kinetics and tissue distribution can help further drive innovation at reduced cost.” – Rami Tzafriri, PhD, Principal Scientist, CBSET “Endovascular Drug Delivery and Drug Elution Systems: First Principles” Abraham Rami Tzafriri, PhD Elazer Reuven Edelman, MD, PhD “…The first principles outlined…serve as a handbook for features […]

Press Release: A Paradigm for Safety Assessment of Energy-Based Devices: CBSET Presents In Vivo Data at SoT 2016

“We have developed a preclinical paradigm for predictably modulating the efficacy of thermal ablation devices while minimizing adverse effects on target and surrounding tissues,” said Dr. John H. Keating, Director of Pathology, CBSET. LEXINGTON, Mass., March 10, 2016 — Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical […]